PANOVISION: Feasibility and Safety of Hybrid IVUS-OCT System

Exclusion Criteria

• •More than 1 stent was planned to deploy in culprit lesion
• •In-stent restenosis
• •Bifurcation lesion with proposed double stent implantation
• •The length of the reference vessel segment proximal or distal to the lesion was less than 5mm
• •The length of the implanted stent was larger than 33mm
• •The diameter of reference vessel was less than 2 mm or larger than 4 mm
• •Lesions were in left main or ostium of right coronary artery
• •The distance between either end of the lesion and the lateral branches larger than 2 mm in diameter was less than 5 mm
• •Angiography revealed thrombosis in culprit vessel
• •Severely calcified lesions or tortuous coronary arteries
• •Decreased blood flow (thrombolysis in myocardial infarction score ≤ 2)
• •Breastfeeding or pregnant women, the subject (or his partner) who had a pregnancy plan during the trial or within 6 months after the end of the trial, and subject who did not agree to use contraception during the trial
• •Participants who had withdrawn from other clinical studies within 3 months or are participating in other clinical trials
• •Acute myocardial infarction occurred within one week prior to screening
• •Cardiac troponin I or cardiac troponin T levels exceed the upper limit of normal reference values within 72 hours of procedure and were of clinical significance
• •Renal insufficiency with creatinine \> 200μmol/L
• •Unsuitable for coronary artery bypass grafting (CABG)
• •Unsuitable for percutaneous coronary intervention;
• •Coronary spasm
• •Chronic total occlusion or subtotal occlusion
• •Severe hemodynamic disturbances or shock
• •History of CABG
• •Coagulation is abnormal and clinically significant
• •Severe heart failure (NYHA III, IV or Left ventricular ejection fraction \< 30%)
• •History of contrast allergy
• •Multi-vessel disease
• •Chemotherapy or planned chemotherapy
• •Investigators consider unsuitable for participants selected for this study